PATCH Act
Summary
The PATCH Act, introduced May 21, 2026, would ban medical debt from consumer credit reports and prohibit creditors from using medical debt in lending decisions. This largely codifies existing CFPB rules and industry practices — major banks have already removed most medical debt from underwriting. No material financial impact on JPMorgan ($JPM), Bank of America ($BAC), Citigroup ($C), or Wells Fargo ($WFC) given it affects <0.1% of revenue.
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.Bill at early stage (referred to committee, no markup)
- 2.Codifies existing CFPB rules and industry practice — minimal new impact
- 3.Revenue impact on US banks ($JPM, $BAC, $C, $WFC) below 0.1% of total revenue
- 4.No direct winners or losers among publicly traded companies; neutral for financial sector
Market Implications
US banking stocks are unaffected by this bill. The legislation is procedurally weak — single sponsor, no companion bill, referred to committee with no further action. Market pricing of bank stocks already reflects the existing CFPB rule. No positioning required. For retail investors, this is a non-event. Focus on other congressional actions with real spending or regulatory teeth.
Full Analysis
This bill, S. 4622, the PATCH Act, was introduced by Sen. Kennedy (R-LA) on May 21, 2026, and referred to the Senate Banking Committee. It is in an early stage with no markup or vote scheduled. The bill amends the Fair Credit Reporting Act to exclude all 'medical debt' from consumer reports and requires the CFPB to revise Regulation B (Equal Credit Opportunity Act) to bar creditors from using medical debt in credit decisions. There is no authorized funding; this is a regulatory mandate on private companies. The CFPB already finalized a rule in January 2023 removing medical debt under $500 from credit reports, and in January 2025 proposed a broader rule targeting all medical debt. Most major lenders (JPM, BAC, C, WFC) already apply internal policies minimizing medical debt weighting. The incremental impact of this bill is therefore marginal — it would codify existing practices, potentially adding enforcement risk for noncompliance but not changing day-to-day operations. The only potential winners are consumers with outstanding medical debt, who may see slight credit score improvements. No publicly traded company stands to gain or lose significant revenue. Collections agencies and credit bureaus (Equifax, Experian, TransUnion — private or foreign-listed) could see negligible data processing changes. Among major US banks, the affected revenue is below 0.1% of total, making this a neutral event for investors. Timeline: remains in committee; companion bill in House not yet introduced. Passage probability before the 2026 midterms is low given early stage and lack of bipartisan co-sponsors.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
No confirming evidence found yet from contracts, insider trades, or congressional activity
What the bill does
Same prohibition on medical debt in credit reports and creditor use.
Who must act
Creditors and credit reporting agencies.
What happens
Bank of America's consumer banking segment (cards, home loans, auto) must update underwriting models; a CFPB rule finalized in 2023 already removed medical debt under $500 from credit reports, and major lenders already discount medical debt, so this largely codifies existing practice.
Stock impact
BAC's consumer banking revenue is ~$35B of total $102.8B revenue; medical debt exclusion has minimal incremental impact beyond current CFPB rule. No material revenue effect.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Deceptive and Unfair Collection of Medical Debt".
GUIDANCE Act of 2026
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Debt Collection Practices (Regulation F); Pay-to-Pay Fees".
A joint resolution providing for congressional disapproval under chapter 8 of title 5, United States Code, of the rule submitted by the Bureau of Consumer Financial Protection relating to the withdrawal of the rule relating to "Fair Credit Reporting; File Disclosure".
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Restoring Integrity to America’s Financial System
This executive order directs the Treasury Department to issue an advisory to financial institutions on risks from non-work authorized populations and their employers, propose regulatory changes to strengthen Bank Secrecy Act customer due diligence and identification requirements, and consider risks from foreign consular IDs. It also directs the CFPB to clarify that deportation risk can affect ability-to-repay assessments for non-work authorized borrowers, and federal financial regulators to issue guidance on credit risks from this population.
Integrating Financial Technology Innovation into Regulatory Frameworks
This executive order directs federal financial regulators to review and streamline regulations that hinder fintech innovation, particularly for small and emerging firms, and requests the Federal Reserve to evaluate expanding access to its payment accounts and services for non-bank and digital asset firms. It aims to reduce barriers to entry and encourage partnerships between fintech firms and traditional financial institutions, with specific deadlines for reviews and reports.